{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:47:50Z","timestamp":1782499670204,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pbio.3003860","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}}],"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["101075865"],"award-info":[{"award-number":["101075865"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00c3\u00a9dicale","doi-asserted-by":"publisher","award":["ConvAJE202110014409"],"award-info":[{"award-number":["ConvAJE202110014409"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009517","name":"Universit\u00c3\u00a9 de Recherche Paris Sciences et Lettres","doi-asserted-by":"publisher","award":["Amor\u00e7age Jeune Equipe"],"award-info":[{"award-number":["Amor\u00e7age Jeune Equipe"]}],"id":[{"id":"10.13039\/501100009517","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Chercher Trouver","award":["Research grant"],"award-info":[{"award-number":["Research grant"]}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"crossref","award":["Starting package"],"award-info":[{"award-number":["Starting package"]}],"id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["INCa-DGOS-Inserm-ITMO Cancer_1800"],"award-info":[{"award-number":["INCa-DGOS-Inserm-ITMO Cancer_1800"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-IDEX-0001-02"],"award-info":[{"award-number":["ANR-10-IDEX-0001-02"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["IP\/SC-18485"],"award-info":[{"award-number":["IP\/SC-18485"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["847718"],"award-info":[{"award-number":["847718"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR 11 LABX"],"award-info":[{"award-number":["ANR 11 LABX"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003990","name":"Conseil R\u00c3\u00a9gional, \u00c3\u017dle-de-France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>One of the first-line treatments for advanced non-small cell lung cancer (NSCLC) are immune checkpoint inhibitors (ICI), which activate the antitumor immune response. Despite their success, ICI remain ineffective in many patients, highlighting the need for strategies to overcome resistance. Most efforts have focused on promoting immune cell infiltration into refractory tumors to improve ICI efficacy. In this work, we mobilize this approach by focusing on Argonaute 2 (Ago2), a pivotal member of the RNA interference pathway. Using two murine models of immunorefractory NSCLC, we demonstrate that tumoral Ago2 suppresses interferon signaling, leading to poor immunogenicity and failure of ICI therapy. Genetic deletion of Ago2 in cancer cells restores interferon signaling and supports immune infiltration of the tumor. Consequently, whereas wild-type tumors are resistant to ICI, tumors devoid of Ago2 become sensitive to treatment. In NSCLC patients treated with ICI, high Ago2 expression and a low interferon signature in tumors correlate with reduced survival. Ago2 is thus a driver of the immunorefractory phenotype observed in NSCLC and may represent a therapeutic target when aiming to sensitize patients to ICI.<\/jats:p>","DOI":"10.1371\/journal.pbio.3003860","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:42:57Z","timestamp":1781804577000},"page":"e3003860","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer"],"prefix":"10.1371","volume":"24","author":[{"given":"Dario Pasquale","family":"Anobile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Barbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Maucotel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Manriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfrid","family":"Richer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Denizeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sedlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Bories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Couderc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Leclere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Sobas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Papillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Mena Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"Tosello-Boari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Burbage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-8442","authenticated-orcid":true,"given":"Eliane","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-2144","authenticated-orcid":true,"given":"Enzo Z.","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"pbio.3003860.ref001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"RL Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"pbio.3003860.ref002","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"N Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"pbio.3003860.ref003","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"P Sharma","year":"2023","journal-title":"Cell"},{"issue":"3","key":"pbio.3003860.ref004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"J Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"pbio.3003860.ref005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/intimm\/dxaf002","article-title":"Cancer immunotherapy in progress-an overview of the past 130 years","volume":"37","author":"H Ikeda","year":"2025","journal-title":"Int Immunol"},{"key":"pbio.3003860.ref006","unstructured":"DeVita, Hellman, and Rosenbergs cancer principles practice of oncology, E-Book (Vincent T. DeVita, StevenA. Rosenberg etc.)."},{"key":"pbio.3003860.ref007","doi-asserted-by":"crossref","first-page":"1384121","DOI":"10.3389\/fimmu.2024.1384121","article-title":"Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors","volume":"15","author":"L Berland","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"pbio.3003860.ref008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"KE de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"pbio.3003860.ref009","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"MD Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"pbio.3003860.ref010","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.ccell.2024.11.002","article-title":"Myeloid effector cells in cancer","volume":"42","author":"P Schol","year":"2024","journal-title":"Cancer Cell"},{"key":"pbio.3003860.ref011","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8+ T cells in the cancer-immunity cycle","volume":"56","author":"JR Giles","year":"2023","journal-title":"Immunity"},{"issue":"7","key":"pbio.3003860.ref012","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Q Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"pbio.3003860.ref013","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-Stimulated Genes: What Do They All Do?","volume":"6","author":"JW Schoggins","year":"2019","journal-title":"Annu Rev Virol"},{"key":"pbio.3003860.ref014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"D Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"pbio.3003860.ref015","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"MS Diamond","year":"2011","journal-title":"J Exp Med"},{"issue":"6","key":"pbio.3003860.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"CS Garris","year":"2018","journal-title":"Immunity"},{"issue":"6411","key":"pbio.3003860.ref017","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"R Cristescu","year":"2018","journal-title":"Science"},{"issue":"4","key":"pbio.3003860.ref018","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune Cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy","volume":"26","author":"Y Liu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pbio.3003860.ref019","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"HN Bell","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"pbio.3003860.ref020","unstructured":"Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers."},{"issue":"9","key":"pbio.3003860.ref021","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/2326-6066.CIR-16-0365","article-title":"The tumor microenvironment regulates sensitivity of murine lung tumors to PD-1\/PD-L1 antibody blockade","volume":"5","author":"HY Li","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"pbio.3003860.ref022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"DP Bartel","year":"2018","journal-title":"Cell"},{"issue":"8","key":"pbio.3003860.ref023","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/nar\/gkr1274","article-title":"Expression determinants of mammalian argonaute proteins in mediating gene silencing","volume":"40","author":"PN Valdmanis","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pbio.3003860.ref024","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-cancerbio-030419-033525","article-title":"Reactivation of endogenous retroelements in cancer development and therapy","volume":"4","author":"CA Ishak","year":"2020","journal-title":"Annu Rev Cancer Biol"},{"issue":"1","key":"pbio.3003860.ref025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/BST20220385","article-title":"RNA interference, an emerging component of antiviral immunity in mammals","volume":"51","author":"DP Anobile","year":"2023","journal-title":"Biochem Soc Trans"},{"key":"pbio.3003860.ref026","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.036","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsrna including endogenous retroviruses","volume":"169","author":"KB Chiappinelli","year":"2017","journal-title":"Cell"},{"issue":"7836","key":"pbio.3003860.ref027","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41586-020-2844-1","article-title":"Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency","volume":"588","author":"P Mehdipour","year":"2020","journal-title":"Nature"},{"issue":"5","key":"pbio.3003860.ref028","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"D Roulois","year":"2015","journal-title":"Cell"},{"issue":"5","key":"pbio.3003860.ref029","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"E Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"12","key":"pbio.3003860.ref030","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0061","article-title":"AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma","volume":"31","author":"A Hashmi","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"pbio.3003860.ref031","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/cancers13040788","article-title":"Argonaute Proteins Take Center Stage in Cancers","volume":"13","author":"I Nowak","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7866","key":"pbio.3003860.ref032","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"595","author":"GK Griffin","year":"2021","journal-title":"Nature"},{"issue":"8","key":"pbio.3003860.ref033","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING promotes the growth of tumors characterized by low antigenicity via IDO activation","volume":"76","author":"H Lemos","year":"2016","journal-title":"Cancer Res"},{"issue":"2","key":"pbio.3003860.ref034","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"C Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"19","key":"pbio.3003860.ref035","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-22-0325","article-title":"An immunogenic model of kras-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations","volume":"82","author":"J Boumelha","year":"2022","journal-title":"Cancer Res"},{"key":"pbio.3003860.ref036","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2014.10.002","article-title":"Small molecule inhibitors of Ago2 decrease Venezuelan equine encephalitis virus replication","volume":"112","author":"C Madsen","year":"2014","journal-title":"Antiviral Res"},{"issue":"2","key":"pbio.3003860.ref037","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/cb200253h","article-title":"Small molecule inhibition of RISC loading","volume":"7","author":"GS Tan","year":"2012","journal-title":"ACS Chem Biol"},{"issue":"32","key":"pbio.3003860.ref038","doi-asserted-by":"crossref","first-page":"24707","DOI":"10.1074\/jbc.M109.062976","article-title":"Identification of small molecules that suppress microRNA function and reverse tumorigenesis","volume":"285","author":"K Watashi","year":"2010","journal-title":"J Biol Chem"},{"key":"pbio.3003860.ref039","doi-asserted-by":"crossref","first-page":"1212086","DOI":"10.3389\/fimmu.2023.1212086","article-title":"Interplay between RNA interference and transposable elements in mammals","volume":"14","author":"A Cornec","year":"2023","journal-title":"Front Immunol"},{"key":"pbio.3003860.ref040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-immunol-101721-033341","article-title":"The immunological conundrum of endogenous retroelements","volume":"41","author":"G Kassiotis","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"pbio.3003860.ref041","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nsmb1141","article-title":"L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells","volume":"13","author":"N Yang","year":"2006","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"pbio.3003860.ref042","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4161\/epi.20706","article-title":"Naturally occurring endo-siRNA silences LINE-1 retrotransposons in human cells through DNA methylation","volume":"7","author":"L Chen","year":"2012","journal-title":"Epigenetics"},{"issue":"5","key":"pbio.3003860.ref043","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2017.10.004","article-title":"An endosiRNA-based repression mechanism counteracts transposon activation during global DNA demethylation in embryonic stem cells","volume":"21","author":"RV Berrens","year":"2017","journal-title":"Cell Stem Cell"},{"key":"pbio.3003860.ref044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.10.008","article-title":"Clonally expanded t cells reveal immunogenicity of rhabdoid tumors","volume":"36","author":"A Leruste","year":"2019","journal-title":"Cancer Cell"},{"key":"pbio.3003860.ref045","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1158\/2159-8290.CD-21-0506","article-title":"Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis","volume":"11","author":"R Chen","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"pbio.3003860.ref046","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s43018-021-00213-9","article-title":"Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response","volume":"2","author":"M Scheller","year":"2021","journal-title":"Nat Cancer"},{"issue":"3","key":"pbio.3003860.ref047","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/0008-5472.CAN-23-1082","article-title":"PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma","volume":"84","author":"H Tao","year":"2024","journal-title":"Cancer Res"},{"issue":"3","key":"pbio.3003860.ref048","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gutjnl-2020-321339","article-title":"SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation","volume":"70","author":"L Ju\u017eni\u0107","year":"2021","journal-title":"Gut"},{"issue":"7882","key":"pbio.3003860.ref049","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-021-03994-2","article-title":"KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements","volume":"598","author":"S-M Zhang","year":"2021","journal-title":"Nature"},{"key":"pbio.3003860.ref050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"KB Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"7952","key":"pbio.3003860.ref051","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41586-023-05720-6","article-title":"Macrophage fumarate hydratase restrains mtRNA-mediated interferon production","volume":"615","author":"A Hooftman","year":"2023","journal-title":"Nature"},{"issue":"1","key":"pbio.3003860.ref052","first-page":"43","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"J Qiu","year":"2023","journal-title":"Nat Cancer"},{"key":"pbio.3003860.ref053","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.omtn.2022.01.016","article-title":"DNA topoisomerase inhibition with the HIF inhibitor acriflavine promotes transcription of lncRNAs in endothelial cells","volume":"27","author":"S Seredinski","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"pbio.3003860.ref054","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001764","article-title":"Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy","volume":"9","author":"V Olivo Pimentel","year":"2021","journal-title":"J Immunother Cancer"},{"key":"pbio.3003860.ref055","article-title":"AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunity","volume":"44","author":"Y Wang","year":"2025","journal-title":"Cell Reports"},{"issue":"1","key":"pbio.3003860.ref056","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev-immunol-082223-044122","article-title":"Molecular mechanisms governing CD8 T cell differentiation and checkpoint inhibitor response in cancer","volume":"43","author":"L Rausch","year":"2025","journal-title":"Annu Rev Immunol."},{"issue":"5","key":"pbio.3003860.ref057","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","article-title":"Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer","volume":"55","author":"A Ravi","year":"2023","journal-title":"Nat Genet"},{"issue":"4","key":"pbio.3003860.ref058","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"JL Benci","year":"2019","journal-title":"Cell"},{"issue":"6","key":"pbio.3003860.ref059","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"JL Benci","year":"2016","journal-title":"Cell"},{"key":"pbio.3003860.ref060","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1186\/s12885-019-5884-x","article-title":"Quantifying argonaute 2 (Ago2) expression to stratify breast cancer","volume":"19","author":"MC Casey","year":"2019","journal-title":"BMC Cancer"},{"issue":"11","key":"pbio.3003860.ref061","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.humpath.2012.02.016","article-title":"Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma","volume":"43","author":"O Vaksman","year":"2012","journal-title":"Hum Pathol"},{"issue":"5","key":"pbio.3003860.ref062","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/hep.26202","article-title":"Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma","volume":"57","author":"N Cheng","year":"2013","journal-title":"Hepatology"},{"issue":"10","key":"pbio.3003860.ref063","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/aps.2015.18","article-title":"Argonaute 2 promotes angiogenesis via the PTEN\/VEGF signaling pathway in human hepatocellular carcinoma","volume":"36","author":"Z Ye","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"pbio.3003860.ref064","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-8722-7-40","article-title":"Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation","volume":"7","author":"S Wu","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"2","key":"pbio.3003860.ref065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbrc.2020.07.058","article-title":"Sequestosome 1 (p62) accumulation in breast cancer cells suppresses progesterone receptor expression via argonaute 2","volume":"531","author":"A Yokota","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"pbio.3003860.ref066","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.celrep.2016.01.034","article-title":"KRAS engages AGO2 to enhance cellular transformation","volume":"14","author":"S Shankar","year":"2016","journal-title":"Cell Rep"},{"issue":"20","key":"pbio.3003860.ref067","article-title":"AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer","volume":"118","author":"JC-Y Tien","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"88","key":"pbio.3003860.ref068","article-title":"Selective control of transposable element expression during T cell exhaustion and anti-PD-1 treatment","volume":"8","author":"P-E Bont\u00e9","year":"2023","journal-title":"Sci Immunol"},{"issue":"1","key":"pbio.3003860.ref069","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"A Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"7","key":"pbio.3003860.ref070","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Y Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"8","key":"pbio.3003860.ref071","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"NE Sanjana","year":"2014","journal-title":"Nat Methods"},{"issue":"1","key":"pbio.3003860.ref072","doi-asserted-by":"crossref","first-page":"100366","DOI":"10.1016\/j.xpro.2021.100366","article-title":"Transcriptome-wide quantification of double-stranded RNAs in live mouse tissues by dsRIP-Seq","volume":"2","author":"Y Gao","year":"2021","journal-title":"STAR Protoc"}],"updated-by":[{"DOI":"10.1371\/journal.pbio.3003860","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3003860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:00:02Z","timestamp":1782496802000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3003860"}},"subtitle":[],"editor":[{"given":"Hans-Uwe","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3003860","relation":{},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}